<p>Electromed, Inc.（紐約證券交易所代碼：ELMD - 免費報告）- Roth Capital 的股票研究分析師在 11 月 12 日星期三向投資者發佈的研究報告中下調了 Electromed 2026 年第二季度每股收益（EPS）預期。Roth Capital 分析師 K. Bauser 現在預計該公司本季度每股收益為 0.25 美元，低於之前的 0.27 美元。Roth Capital 對該股票給予 &#34;買入&#34; 評級，目標價為 36.00 美元。Roth Capital 還對 Electromed 2026 年第三季度的每股收益預期為 0.25 美元，2026 財年的每股收益預期為 1.05 美元，2027 財年的每股收益預期為 1.25 美元。</p>
<p>其他分析師最近也發佈了關於該股票的研究報告。Lake Street Capital 於 8 月 27 日星期三開始覆蓋 Electromed 的股票。他們給予該公司的 &#34;買入&#34; 評級和 36.00 美元的目標價。Loop Capital 在 8 月 27 日星期三的研究報告中對 Electromed 設置了 36.00 美元的目標價。最後，Zacks Research 在 10 月 27 日星期一的研究報告中將 Electromed 的評級從 &#34;強力買入&#34; 下調至 &#34;持有&#34;。一位股票研究分析師給予該股票 &#34;強力買入&#34; 評級，兩位給予 &#34;買入&#34; 評級，一位給予 &#34;持有&#34; 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 &#34;買入&#34;，平均目標價為 36.50 美元。</p>
<p><strong>閲讀我們對 Electromed 的最新分析</strong></p>
<h2>Electromed 股價下跌 5.0%</h2>
<p>Electromed 股票在星期五交易中下跌 1.31 美元，報 25.04 美元。該公司交易了 7,093 股，低於其平均交易量 77,355 股。該公司的市值為 2.0974 億美元，市盈率為 33.39，貝塔值為 0.40。該公司的 50 日移動平均線為 24.60 美元，200 日移動平均線為 21.98 美元。Electromed 的 52 周低點為 17.73 美元，52 周高點為 35.56 美元。</p>
<h2>內部交易活動</h2>
<p>在其他新聞中，董事 Andrew Summers 於 9 月 11 日星期四出售了 3,153 股該公司的股票。股票以平均價格 24.42 美元出售，總交易額為 76,996.26 美元。該交易已在與 SEC 的法律文件中披露，可以通過此鏈接訪問。目前，內部人士持有該股票的 10.50%。</p>
<h2>機構投資者對 Electromed 的看法</h2>
<p>大型投資者最近增加或減少了對該公司的持股。Millennium Management LLC 在第一季度將其在 Electromed 的持股增加了 362.7%。Millennium Management LLC 現在擁有 194,519 股該公司的股票，價值 4,641,000 美元，此前在上個季度購買了額外的 152,480 股。Geode Capital Management LLC 在第二季度將其在 Electromed 的持股增加了 128.3%。Geode Capital Management LLC 現在擁有 155,540 股該公司的股票，價值 3,421,000 美元，此前在上個季度購買了額外的 87,401 股。Acadian Asset Management LLC 在第一季度將其在 Electromed 的持股增加了 25.2%。Acadian Asset Management LLC 現在擁有 267,975 股該公司的股票，價值 6,388,000 美元，此前在該期間購買了額外的 53,872 股。摩根大通在第二季度將其在 Electromed 的持股增加了 117.7%。摩根大通現在擁有 64,371 股該公司的股票，價值 1,416,000 美元，此前在上個季度收購了額外的 34,799 股。最後，Jane Street Group LLC 在第一季度將其在 Electromed 的持股增加了 136.3%。Jane Street Group LLC 現在擁有 56,263 股該公司的股票，價值 1,342,000 美元，此前在上個季度購買了額外的 32,456 股。對沖基金和其他機構投資者持有該公司 40.82% 的股票。</p>
<h2>關於 Electromed</h2>
<p>（獲取免費報告）</p>
<p>Electromed, Inc 開發、製造、營銷和銷售氣道清理治療及相關產品，應用高頻胸壁振盪（HFCWO）治療，服務於美國及國際各年齡段的患者。該公司為肺功能受損的患者提供 SmartVest 氣道清理系統，包括支氣管擴張症和囊性纖維化患者，以及神經肌肉疾病患者，如腦癱和肌萎縮側索硬化症；SmartVest SQL 系統；SmartVest Clearway 系統，包括一個充氣治療服、一個可編程氣脈衝發生器和一個專利單管，能夠將氣脈衝從發生器傳遞到服裝上，以在胸壁上產生振盪壓力；以及 SmartVest Connect，一種無線技術，允許醫生與患者之間的數據連接，以跟蹤治療效果並協作治療決策。</p>
<h2>閲讀更多</h2>
<ul>
<li>我們更看好的五隻股票比 Electromed 更好</li>
<li>零售股票投資，解析</li>
<li>CRWD 股票在財報前達到關鍵拐點</li>
<li>3 只天然氣股票提供優厚的股息收益</li>
<li>Rigetti 的第三季度失利揭示量子資金和時機壓力</li>
<li>大型股定義及如何投資</li>
<li>Monolithic Power 在 2025 年激增——是時候買入還是持有？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMTUQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMTUQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Electromed 嗎？</h2>
<p>在你考慮 Electromed 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Electromed 並不在名單上。</p>
<p>雖然 Electromed 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ELMD

<p>Roth Capital 將 Electromed 2026 年第二季度每股收益預期從 0.27 美元下調至 0.25 美元，維持 “買入” 評級，目標價為 36 美元。其他分析師也對該股票給予積極評價，平均目標價為 36.50 美元。Electromed 的股票最近下跌了 5%，至 25.04 美元。機構投資者正在調整其持股，Millennium Management 和 Geode Capital 的持股顯著增加。Electromed 開發用於肺部護理的氣道清理治療產品，包括 SmartVest 系統</p>

<p>Electromed, Inc. (NYSE:ELMD - Free Report) - Equities research analysts at Roth Capital lowered their Q2 2026 earnings per share (EPS) estimates for shares of Electromed in a research note issued to investors on Wednesday, November 12th. Roth Capital analyst K. Bauser now anticipates that the company will post earnings of $0.25 per share for the quarter, down from their prior estimate of $0.27. Roth Capital has a &#34;Buy&#34; rating and a $36.00 price objective on the stock. Roth Capital also issued estimates for Electromed's Q3 2026 earnings at $0.25 EPS, FY2026 earnings at $1.05 EPS and FY2027 earnings at $1.25 EPS.</p>
<div class="lb-trans"><p>Electromed, Inc.（紐約證券交易所代碼：ELMD - 免費報告）- Roth Capital 的股票研究分析師在 11 月 12 日星期三向投資者發佈的研究報告中下調了 Electromed 2026 年第二季度每股收益（EPS）預期。Roth Capital 分析師 K. Bauser 現在預計該公司本季度每股收益為 0.25 美元，低於之前的 0.27 美元。Roth Capital 對該股票給予 &#34;買入&#34; 評級，目標價為 36.00 美元。Roth Capital 還對 Electromed 2026 年第三季度的每股收益預期為 0.25 美元，2026 財年的每股收益預期為 1.05 美元，2027 財年的每股收益預期為 1.25 美元。</p>
</div><p>Other analysts also recently issued research reports about the stock. Lake Street Capital began coverage on shares of Electromed in a report on Wednesday, August 27th. They issued a &#34;buy&#34; rating and a $36.00 target price for the company. Loop Capital set a $36.00 price target on Electromed in a research report on Wednesday, August 27th. Finally, Zacks Research cut Electromed from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of &#34;Buy&#34; and an average price target of $36.50.</p>
<div class="lb-trans"><p>其他分析師最近也發佈了關於該股票的研究報告。Lake Street Capital 於 8 月 27 日星期三開始覆蓋 Electromed 的股票。他們給予該公司的 &#34;買入&#34; 評級和 36.00 美元的目標價。Loop Capital 在 8 月 27 日星期三的研究報告中對 Electromed 設置了 36.00 美元的目標價。最後，Zacks Research 在 10 月 27 日星期一的研究報告中將 Electromed 的評級從 &#34;強力買入&#34; 下調至 &#34;持有&#34;。一位股票研究分析師給予該股票 &#34;強力買入&#34; 評級，兩位給予 &#34;買入&#34; 評級，一位給予 &#34;持有&#34; 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 &#34;買入&#34;，平均目標價為 36.50 美元。</p>
</div><p><strong>Read Our Latest Analysis on Electromed</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 Electromed 的最新分析</strong></p>
</div><h2>Electromed Trading Down 5.0%</h2>
<div class="lb-trans"><h2>Electromed 股價下跌 5.0%</h2>
</div><p>Electromed stock traded down $1.31 during trading on Friday, hitting $25.04. 7,093 shares of the company were exchanged, compared to its average volume of 77,355. The company has a market capitalization of $209.74 million, a P/E ratio of 33.39 and a beta of 0.40. The business's 50 day moving average is $24.60 and its 200 day moving average is $21.98. Electromed has a 52 week low of $17.73 and a 52 week high of $35.56.</p>
<div class="lb-trans"><p>Electromed 股票在星期五交易中下跌 1.31 美元，報 25.04 美元。該公司交易了 7,093 股，低於其平均交易量 77,355 股。該公司的市值為 2.0974 億美元，市盈率為 33.39，貝塔值為 0.40。該公司的 50 日移動平均線為 24.60 美元，200 日移動平均線為 21.98 美元。Electromed 的 52 周低點為 17.73 美元，52 周高點為 35.56 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部交易活動</h2>
</div><p>In other news, Director Andrew Summers sold 3,153 shares of the company's stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $24.42, for a total transaction of $76,996.26. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 10.50% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他新聞中，董事 Andrew Summers 於 9 月 11 日星期四出售了 3,153 股該公司的股票。股票以平均價格 24.42 美元出售，總交易額為 76,996.26 美元。該交易已在與 SEC 的法律文件中披露，可以通過此鏈接訪問。目前，內部人士持有該股票的 10.50%。</p>
</div><h2>Institutional Investors Weigh In On Electromed</h2>
<div class="lb-trans"><h2>機構投資者對 Electromed 的看法</h2>
</div><p>Large investors have recently added to or reduced their stakes in the company. Millennium Management LLC lifted its holdings in Electromed by 362.7% during the first quarter. Millennium Management LLC now owns 194,519 shares of the company's stock valued at $4,641,000 after purchasing an additional 152,480 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Electromed by 128.3% in the second quarter. Geode Capital Management LLC now owns 155,540 shares of the company's stock worth $3,421,000 after purchasing an additional 87,401 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in Electromed by 25.2% in the 1st quarter. Acadian Asset Management LLC now owns 267,975 shares of the company's stock worth $6,388,000 after buying an additional 53,872 shares during the period. JPMorgan Chase &amp; Co. lifted its position in shares of Electromed by 117.7% during the second quarter. JPMorgan Chase &amp; Co. now owns 64,371 shares of the company's stock worth $1,416,000 after acquiring an additional 34,799 shares in the last quarter. Finally, Jane Street Group LLC grew its position in shares of Electromed by 136.3% in the first quarter. Jane Street Group LLC now owns 56,263 shares of the company's stock valued at $1,342,000 after purchasing an additional 32,456 shares in the last quarter. Hedge funds and other institutional investors own 40.82% of the company's stock.</p>
<div class="lb-trans"><p>大型投資者最近增加或減少了對該公司的持股。Millennium Management LLC 在第一季度將其在 Electromed 的持股增加了 362.7%。Millennium Management LLC 現在擁有 194,519 股該公司的股票，價值 4,641,000 美元，此前在上個季度購買了額外的 152,480 股。Geode Capital Management LLC 在第二季度將其在 Electromed 的持股增加了 128.3%。Geode Capital Management LLC 現在擁有 155,540 股該公司的股票，價值 3,421,000 美元，此前在上個季度購買了額外的 87,401 股。Acadian Asset Management LLC 在第一季度將其在 Electromed 的持股增加了 25.2%。Acadian Asset Management LLC 現在擁有 267,975 股該公司的股票，價值 6,388,000 美元，此前在該期間購買了額外的 53,872 股。摩根大通在第二季度將其在 Electromed 的持股增加了 117.7%。摩根大通現在擁有 64,371 股該公司的股票，價值 1,416,000 美元，此前在上個季度收購了額外的 34,799 股。最後，Jane Street Group LLC 在第一季度將其在 Electromed 的持股增加了 136.3%。Jane Street Group LLC 現在擁有 56,263 股該公司的股票，價值 1,342,000 美元，此前在上個季度購買了額外的 32,456 股。對沖基金和其他機構投資者持有該公司 40.82% 的股票。</p>
</div><h2>About Electromed</h2>
<div class="lb-trans"><h2>關於 Electromed</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.</p>
<div class="lb-trans"><p>Electromed, Inc 開發、製造、營銷和銷售氣道清理治療及相關產品，應用高頻胸壁振盪（HFCWO）治療，服務於美國及國際各年齡段的患者。該公司為肺功能受損的患者提供 SmartVest 氣道清理系統，包括支氣管擴張症和囊性纖維化患者，以及神經肌肉疾病患者，如腦癱和肌萎縮側索硬化症；SmartVest SQL 系統；SmartVest Clearway 系統，包括一個充氣治療服、一個可編程氣脈衝發生器和一個專利單管，能夠將氣脈衝從發生器傳遞到服裝上，以在胸壁上產生振盪壓力；以及 SmartVest Connect，一種無線技術，允許醫生與患者之間的數據連接，以跟蹤治療效果並協作治療決策。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>閲讀更多</h2>
</div><ul>
<li>Five stocks we like better than Electromed</li>
<li>Retail Stocks Investing, Explained</li>
<li>CRWD Stock Hits Key Inflection Point Ahead of Earnings</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>Rigetti’s Q3 Miss Reveals Quantum Funding and Timing Pressures</li>
<li>Large Cap Stock Definition and How to Invest</li>
<li>Monolithic Power Surges in 2025—Time to Buy or Hold?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Electromed 更好</li>
<li>零售股票投資，解析</li>
<li>CRWD 股票在財報前達到關鍵拐點</li>
<li>3 只天然氣股票提供優厚的股息收益</li>
<li>Rigetti 的第三季度失利揭示量子資金和時機壓力</li>
<li>大型股定義及如何投資</li>
<li>Monolithic Power 在 2025 年激增——是時候買入還是持有？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMTUQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=ELMD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Electromed Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Electromed 嗎？</h2>
</div><p>Before you consider Electromed, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Electromed 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Electromed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Electromed 並不在名單上。</p>
</div><p>While Electromed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Electromed 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Roth Capital 對 Electromed 第二季度的收益持負面展望